Literature DB >> 10332461

Sphincteric stent versus external sphincterotomy in spinal cord injured men: prospective randomized multicenter trial.

M B Chancellor1, C Bennett, A R Simoneau, M V Finocchiaro, C Kline, J K Bennett, J E Foote, B G Green, S H Martin, R W Killoran, J A Crewalk, D A Rivas.   

Abstract

PURPOSE: In a prospective randomized multicenter trial we compared the treatment results of conventional external sphincterotomy with those of UroLume sphincteric stent prosthesis placement in men with spinal cord injury and external detrusor-sphincter dyssynergia.
MATERIALS AND METHODS: We randomized 57 men with spinal cord injury in whom urodynamics verified external detrusor-sphincter dyssynergia into 2 groups to undergo either sphincter defeating procedure. We compared the primary urodynamic parameter of maximum detrusor pressure, and secondary urodynamic parameters of bladder capacity and post-void residual urine volume in men who underwent sphincterotomy or sphincteric stent placement. Parameters were measured preoperatively, and 3, 6, 12 and 24 months postoperatively. Patients completed questionnaires regarding voiding sensation and quality of life issues at each followup visit.
RESULTS: Demographic data of the 26 patients treated with sphincterotomy and the 31 treated with sphincteric stent placement were statistically similar. Preoperatively mean maximum detrusor pressure plus or minus standard deviation in sphincterotomy and stent cases was 98.3 +/- 27.6 and 95.7 +/- 27.7 cm. water, respectively (p = 0.73). At 12 months mean maximum detrusor pressure decreased to 48.9 +/- 16.4 and 52.6 +/- 31.6 cm. water in the sphincterotomy and stent groups, respectively (p = 0). Preoperatively mean bladder capacity in sphincterotomy and stent cases was 245 +/- 158 and 251 +/- 145 ml., respectively (p = 0.87). Bladder capacity did not change significantly in either treatment group throughout followup. Preoperatively mean post-void residual urine volume in the sphincterotomy and stent groups was 212 +/- 163 and 168 +/- 114 ml., respectively (p = 0.33). Residual urine volume decreased in each group at some but not all followup evaluations. The duration of hospitalization was greater for sphincterotomy than stenting (p = 0.036). Six stents required explantation.
CONCLUSIONS: The UroLume stent is as effective as conventional external sphincterotomy for treating external detrusor-sphincter dyssynergia. However, sphincteric stent placement is advantageous because it involves shorter hospitalization and is potentially reversible.

Entities:  

Mesh:

Year:  1999        PMID: 10332461

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  Neurogenic bladder: from diagnosis to management.

Authors:  Ellen Goldmark; Benjamin Niver; David A Ginsberg
Journal:  Curr Urol Rep       Date:  2014-10       Impact factor: 3.092

2.  Predictors of outcome for urethral injection of botulinum toxin to treat detrusor sphincter dyssynergia in men with spinal cord injury.

Authors:  J M Soler; J G Previnaire; N Hadiji
Journal:  Spinal Cord       Date:  2015-12-29       Impact factor: 2.772

Review 3.  Urinary tract infections in patients with spinal cord lesions: treatment and prevention.

Authors:  F Biering-Sørensen; P Bagi; N Høiby
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Management of neurogenic bladder in patients with multiple sclerosis.

Authors:  Véronique Phé; Emmanuel Chartier-Kastler; Jalesh N Panicker
Journal:  Nat Rev Urol       Date:  2016-03-31       Impact factor: 14.432

5.  Male urinary incontinence: prevalence, risk factors, and preventive interventions.

Authors:  Tatyana A Shamliyan; Jean F Wyman; Ryan Ping; Timothy J Wilt; Robert L Kane
Journal:  Rev Urol       Date:  2009

Review 6.  Neurogenic bladder - concepts and treatment recommendations.

Authors:  José Carlos Truzzi; Fernando Gonçalves de Almeida; Carlos Alberto Sacomani; Joceara Reis; Flávio Eduardo Trigo Rocha
Journal:  Int Braz J Urol       Date:  2022 Mar-Apr       Impact factor: 1.541

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.